Dr. Cyrus D. Mozayeni is co-founder, President and CEO of Vedere Bio and Entrepreneur-in-Residence at Atlas Venture. Prior to Vedere, he was co-founder of CODA Biotherapeutics, and Oncorus (NASDAQ: ONCR) where he served as President and CBO. Prior to Oncorus, Cyrus served as VP and global head of business development and alliance management at bluebird bio (NASDAQ: BLUE), where his efforts led to a clinical-stage CAR T-cell program (ABECMA®, idecabtagene vicleucel) in collaboration with Celgene, and a successful IPO. Cyrus earned his Sc.B. in neuroscience from Brown University, his M.D. from the University of Virginia School of Medicine and his MBA from the Kellogg School of Management at Northwestern University. He is a licensed physician, and a Fellow of the Academy of Wilderness Medicine.

Dr. Veres joins Vedere Bio II from BioMarin, where he served as Vice President, Head of Gene Therapy Research, focusing on AAV platform discovery and identifying new therapeutic indications in gene therapy. Prior to this role, Dr. Veres was Vice President of Pre-clinical Research at bluebird bio, where he initiated and coordinated multiple research programs including viral gene delivery to correct genetic and acquired diseases. He also led several projects from pre-clinical research to clinical development including ZYNTEGLO® and SKYSONA™. Prior to joining bluebird bio, Dr. Veres served as Vice President of Research and Development at Applied Genetic Technologies Corporation, a gene therapy company focused on developing treatments for rare conditions of the eye, lung and liver. Dr. Veres holds a Ph.D. in Genetics and Biochemistry from the University of Szeged, Hungary.

Mark Gaffney brings over 20 years’ experience to us and serves as our Chief Operating Officer at Vedere Bio II. He served as Chief Business Officer at Vedere Bio, which included a leading role in its acquisition by Novartis. Prior to his time with the Vedere companies, he led corporate development at Cyclerion Therapeutics, and over a ten-year career with Ironwood Pharmaceuticals, he led the corporate legal and business development functions. Mark started his legal career at Ropes & Gray, and prior to becoming a lawyer, spent five years serving in the United States Air Force. Mark holds a bachelor’s degree in mechanical engineering from the University of Pennsylvania and a law degree from Boston University.

Michael Murtagh is the Senior Vice President, Regulatory Affairs at Vedere Bio II. Prior to Vedere, he served as Vice President, Regulatory Affairs, at Astellas Gene Therapies (formerly known as Audentes Therapeutics) where he led the regulatory strategy of multiple gene therapy programs from research through clinical development. Before Astellas, Michael served as Director, Regulatory Affairs at BioMarin Pharmaceutical Inc. where he was the regulatory lead on the Brineura (cerliponase alfa) and Talzenna (talozaprib) programs from research through clinical development. He received a B.S. in biology from the University of San Francisco.

Dr. Karen Guerin is the Senior Director of Virology at Vedere Bio. Prior to joining Vedere, she was an associate director at Addgene, where she focused on AAV production and quality control. She also served as a project team leader and research investigator in gene therapy at the Novartis Institutes for BioMedical Research and was a Research Fellow at Children’s Hospital Boston. Karen holds a B.Sc in neurosciences from the University of Toulouse, an M.Sc in neurosciences and neuropharmacology from the University of Bordeaux, and a Ph.D. in vision science and molecular biology from the University of California, Berkeley.

Daniel Zimmer is Senior Director, Program Lead at Vedere Bio. Prior to joining Vedere, he was a Senior Principal Investigator at Cyclerion, where he led the soluble guanylate cyclase stimulator discovery program, developed and executed pharmacology strategy, and contributed to clinical development of the oral soluble guanylate cyclase stimulators praliciguat and olinciguat. Prior to Cyclerion, he was a Principal Investigator at Ironwood Pharmaceuticals where he led multiple discovery programs. He holds S.B. degrees in biology and chemistry from MIT and a Ph.D. in Molecular Biophysics and Biochemistry from Yale University.